AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 172 min read$TPST

Tempest Therapeutics, Inc. (TPST): Entry into a Material Definitive Agreement

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform -Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year

Original reporting
SEC EDGAR 8-K
Published Sep 17, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$TPST
Bullish
high confidence
Mentioned
$TPST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TPSTBullishMed
01

Why it matters

The agreement expands Tempest's technology suite, potentially accelerating its pipeline and offering broader therapeutic reach across hematologic malignancies and autoimmune diseases.

02

Market read

A material partnership for a small‑cap biotech, likely to generate modest price movement and sector interest.

03

What to watch

Regulatory pathway for lentiviral in‑vivo CAR‑T is less established than LNP, adding uncertainty.

Relevance 6/10Novelty 8/10Timing: filed Sep 17 2026

Background

Tempest Therapeutics (Nasdaq: TPST) announced an exclusive option to license a CD7‑targeted lentiviral vector platform from Hebei Senlang Biotechnology, complementing its existing lipid‑nanoparticle CAR‑T delivery approach.

Company-level read

Ticker impact

$TPSTBullishHigh confidence
Context

Tempest Therapeutics filed an 8‑K announcing an exclusive option to license Senlang's CD7‑targeted lentiviral CAR‑T platform, a material definitive agreement for its pipeline.

Expected impact

moderate upside as investors price in expanded pipeline potential

Evidence & confidence

First‑report of a strategic partnership; biotech investors typically react positively to new platform access, especially when it complements existing technology.

Market effects

Sector

strengthens the in‑vivo CAR‑T niche and may spur interest in similar biotech collaborations

Regional

limited to US biotech sector; no broader regional effect

Global

minor, confined to biotech investors

Counterpoint

What could challenge this read

Deal may dilute focus on Tempest's existing LNP platform and increase execution risk.

Key entities

  • Company
    Tempest Therapeutics

    Clinical‑stage biotech developing in‑vivo CAR‑T therapies.

  • Company
    Hebei Senlang Biotechnology

    Chinese cell‑therapy firm providing the CD7‑lentiviral platform.

Read at source← All news

Related articles

SEP 15
$TPSTHigh

Tempest Therapeutics stock surges on Senlang CAR-T deal

Tempest Therapeutics (NASDAQ:TPST) shares rose 21% after announcing an exclusive option agreement with Hebei Senlang Biotechnology to license Senlang’s CD7-targeted lentiviral vector platform, including a Phase 1 BCMA/GPRC5D dual-targeting candidate for multiple myeloma. The deal complements Tempest’s existing in vivo CAR-T platform, set to enter clinical trials later this year.

investing.com2 min
AUG 17
$TPSTMed

Tempest Q2 Loss Narrows; Advances In Vivo CAR-T Pipeline With TPST-4003

Tempest Therapeutics (TPST) reported Q2 2026 net loss of $5.2M, or $0.34/share, versus $7.9M, or $2.07/share a year earlier. R&D fell to $1.8M and G&A to $3.4M. Cash was $0.8M at June 30. The company advanced TPST-4003 (CD19/BCMA via CD7 mRNA/LNP) with a Senlang collaboration and a China investigator trial starting Q4 2026, and cited interim TPST-2003 data. Shares were up in premarket.

rttnews.com6 min
AUG 13
$TPSTMed

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T,

SEC EDGAR 8-K6 min
OCT 3
$7203.TMed

Chinese auto show debuts in Argentina as sales surge

Argentina hosts its first Chinese auto show as Chinese brands gain market share, accounting for 10% of August sales. BYD 002594.SZ is now the ninth best-selling brand. Over 20 Chinese brands, including Geely 0175.HK and Chery 9973.HK, were displayed. Toyota 7203.T plans a $1.34B EV plant. Tesla may enter Argentina. Car sales fell 13% YoY due to market adjustment and high interest rates.

manilatimes.net2 min